Paricalcitol, marketed by Abbott Laboratories under the trade name Zemplar, is a drug used for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. It is an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D2. Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors.
Related Prodcuts:
Paricalcitol CD ring intermediate; Paricalcitol Impurity 19; Paricalcitol Intermediate A; Paricalcitol Intermediate(1263504-45-5; 138079-58-0)